Redefining Hypertension Therapy: Experience the Difference with Ultrasound Renal Denervation

 

 

  • What Makes Paradise uRDN Unique?
    Joseph Garasic, MD
     
  • Panel Discussion
    Ajay Kirtane, MD, All Panelists
     
  • What Have We Learned from the Data?
    Naomi Fisher, MD
     
  • Panel Discussion
    Ajay Kirtane, MD, All Panelists
     
  • How Can Hospitals Build a Robust uRDN Program?
    Sripal Bangalore, MD
     
  • Panel Discussion
    Ajay Kirtane, MD, All Panelists

 

PANELISTS

Ajay Kirtane, MD, SM  

Ajay Kirtane, MD, SM
NewYork-Presbyterian Hospital
New York, NY

 Joseph M. Garasic, MD  

Joseph M. Garasic, MD
Massachusetts General Hospital
Boston, MA
Sripal Bangalore, MD, MHA  

Sripal Bangalore, MD, MHA
NYU Langone Health
New York, NY

 Naomi D.L. Fisher, MD  

Naomi D.L. Fisher, MD
Brigham and Women’s Hospital
Boston, MA

 

This program was supported by: 

Recor-Logo

Click here to learn more.

The Paradise System is FDA approved for sale in the United States and is CE marked and is approved for sale in markets where the CE mark is accepted, per approved indications for use. For investigational use only in Japan.